Novo reveals more Ozempic data on change in body weight by baseline BMI
June 23, 2018 at 10:00 AM EDT
COPENHAGEN, June 23 (Reuters) - Diabetes drugmaker Novo Nordisk presented a post-hoc analysis of the SUSTAIN 7 trial comparing treatment effect in body weight across baseline BMI subgroups receiving Novo's Ozempic or Eli Lilly's dulaglutide, marketed as Trulicity.
